ZYDUS LIFESCIENCES
|
ZYDUS LIFESCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 50.10 | 44.99 | 38.36 | 19.37 | 43.82 |
| CEPS(Rs) | 63.96 | 54.98 | 45.68 | 26.92 | 29.68 |
| DPS(Rs) | - | 11.00 | 3.00 | 6.00 | 2.50 |
| Book NAV/Share(Rs) | 269.50 | 238.10 | 197.11 | 173.08 | 166.01 |
| Tax Rate(%) | 24.09 | 23.43 | 20.33 | 22.70 | 18.03 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 13.91 | 15.09 | 13.97 | 10.53 | 10.74 |
| EBIT Margin(%) | 13.66 | 13.61 | 12.89 | 8.02 | 10.03 |
| Pre Tax Margin(%) | 12.81 | 13.19 | 12.68 | 7.64 | 9.60 |
| PAT Margin (%) | 9.73 | 10.10 | 10.10 | 5.90 | 7.87 |
| Cash Profit Margin (%) | 12.45 | 12.11 | 12.12 | 8.03 | 10.28 |
| Performance Ratios | |||||
| ROA(%) | 11.81 | 14.77 | 14.70 | 7.82 | 9.40 |
| ROE(%) | 19.69 | 21.08 | 20.52 | 11.60 | 15.51 |
| ROCE(%) | 21.39 | 26.06 | 24.90 | 13.64 | 15.30 |
| Asset Turnover(x) | 1.21 | 1.46 | 1.46 | 1.32 | 1.19 |
| Sales/Fixed Asset(x) | 1.85 | 2.20 | 1.98 | 1.88 | 1.69 |
| Working Capital/Sales(x) | 12.32 | 5.71 | 6.24 | 7.57 | 6.92 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.54 | 0.46 | 0.50 | 0.53 | 0.59 |
| Receivable days | 33.55 | 37.17 | 46.37 | 41.75 | 39.94 |
| Inventory Days | 33.80 | 29.51 | 32.98 | 38.39 | 42.95 |
| Payable days | 149.82 | 150.48 | 147.51 | 145.80 | 166.64 |
| Valuation Parameters | |||||
| PER(x) | 17.39 | 19.69 | 26.20 | 25.37 | 7.96 |
| PCE(x) | 13.62 | 16.11 | 22.01 | 18.26 | 11.75 |
| Price/Book(x) | 3.23 | 3.72 | 5.10 | 2.84 | 2.10 |
| Yield(%) | - | 1.24 | 0.30 | 1.22 | 0.72 |
| EV/Net Sales(x) | 3.61 | 3.84 | 5.16 | 2.92 | 2.57 |
| EV/Core EBITDA(x) | 10.91 | 12.15 | 17.78 | 12.44 | 10.88 |
| EV/EBIT(x) | 13.88 | 14.36 | 20.61 | 18.51 | 13.08 |
| EV/CE(x) | 2.52 | 3.29 | 4.89 | 2.69 | 1.45 |
| M Cap / Sales | 3.23 | 3.83 | 5.17 | 2.89 | 2.36 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 16.81 | 18.90 | 13.40 | 14.08 | 4.90 |
| Core EBITDA Growth(%) | 22.19 | 29.72 | 40.08 | 13.49 | 3.04 |
| EBIT Growth(%) | 13.55 | 27.15 | 79.81 | -8.28 | 14.68 |
| PAT Growth(%) | 8.92 | 20.45 | 91.39 | -13.95 | 5.48 |
| EPS Growth(%) | 11.37 | 17.26 | 98.06 | -55.80 | 110.32 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.43 | 0.13 | 0.04 | 0.07 | 0.25 |
| Current Ratio(x) | 1.27 | 1.89 | 2.14 | 1.81 | 1.55 |
| Quick Ratio(x) | 0.91 | 1.45 | 1.50 | 1.19 | 1.07 |
| Interest Cover(x) | 16.09 | 32.55 | 60.22 | 20.94 | 23.35 |
| Total Debt/Mcap(x) | 0.13 | 0.04 | 0.01 | 0.02 | 0.12 |
Compare Financial Ratios of peers of ZYDUS LIFESCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ZYDUS LIFESCIENCES | ₹113,101.5 Cr | -1.3% | 2.7% | 13.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹465,507.0 Cr | 2.8% | 7.4% | 14.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹190,744.0 Cr | 6.4% | 8.3% | 0.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹168,250.0 Cr | 2.1% | 8.7% | 47.7% | Stock Analytics | |
| CIPLA | ₹116,213.0 Cr | 0.5% | 3.6% | -5.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,980.0 Cr | -7.6% | -2.2% | -5.8% | Stock Analytics | |
ZYDUS LIFESCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ZYDUS LIFESCIENCES | -1.3% |
2.7% |
13.2% |
| SENSEX | -1.4% |
4.4% |
-7.6% |
You may also like the below Video Courses
